DataMeds AI (NASDAQ:MEDS) has regained compliance with Nasdaq’s minimum stockholders’ equity requirement, following a notification dated October 19, 2026. The requirement is $2.5 million, and the company’s October 13 filing confirmed equity exceeded that threshold. An October 16 filing supplied additional details on the events behind the increase.
Nasdaq had notified DataMeds of delisting proceedings in April over bid-price and equity deficiencies. Bid-price compliance was restored in June. The company may face delisting if it fails to demonstrate compliance when filing its next periodic report.
DataMeds AI (NASDAQ:MEDS) outlined subsidiary Corexa Health’s peptide business plans following the FDA’s proposed interim policy for compounding certain peptides. The proposal follows an advisory committee recommendation to loosen restrictions on six peptides; it is not yet effective.
Corexa Pharmacy plans to fill prescriptions for eligible peptides once the policy takes effect. It has begun reviewing drug-substance suppliers and intends to formalize contracts in the coming weeks. Corexa Distribution, licensed in all 50 states, plans to work with prospective manufacturers and its network of 6,500+ independent pharmacies to expand access.
DataMeds expects the peptide market to be predominantly cash pay initially, potentially reducing Corexa Pharmacy’s exposure to insurance reimbursement challenges. Its Tech & Hub division routes prescriptions to Corexa Pharmacy or a patient’s chosen local pharmacy.
DataMeds AI (MEDS) signed an exclusive agreement with REBOOT Health AI for U.S. direct-to-consumer rights to its care management platform. The agreement covers licensing, revenue sharing and marketing for a platform supporting patients taking GLP-1 weight management medications. DataMeds will share revenue from subscriptions related to the platform.
DataMeds plans to integrate REBOOT's technology into its Health Lives Here mobile app, conduct pilot programs and launch commercially. Planned weight care support modules will be offered through monthly subscriptions. REBOOT's patent family includes six patents and six pending applications. DataMeds expects the subscription services also to drive revenue from pharmacy dispensing, nutraceutical sales, diagnostic lab testing and physician services. The app is available on Android and iOS.
DataMeds AI (MEDS) has implemented cost controls, primarily reducing corporate management positions, to focus workforce spending on commercializing ChemoFx.
The diagnostic test helps oncologists select chemotherapy regimens, initially for gynecologic cancers only. ChemoFx was recently included for the first time in a Humana Medicaid coverage policy for gynecologic cancers. The update follows DataMeds' September 11, 2026 acquisition of Helomics, including its Predictive Oncology division.
Predictive Oncology controls over 70,000 de-identified tumor samples across over 130 tumor types, including approximately 20,000 ovarian cancer samples. DataMeds intends to seek research collaborations using data from the samples and is preparing additional ChemoFx data analyses for peer review. Discussions have begun with healthcare organizations about adding ChemoFx to cancer testing programs where appropriate.
DataMeds AI (NASDAQ:MEDS) announced that subsidiary Helomics received Humana Medicaid coverage for its ChemoFx chemotherapy-response assay in gynecologic cancers. The policy became effective July 22, 2026. ChemoFx tests a patient's live tumor cells to help inform chemotherapy selection and is billed under CPT codes 81535 and 81536.
Members may be eligible for testing during initial biopsy or surgery, for recurrent or treatment-refractory cancer, when recommended treatment cannot be tolerated, or for rare cancers without established treatment guidelines. Coverage does not extend to all Humana plans. Helomics previously invested in laboratory automation. DataMeds said the laboratory is positioned to support additional volume as coverage grows and is preparing data for publication to support label expansion. ChemoFx is a laboratory-developed test without FDA clearance or approval.
DataMeds AI (MEDS) filed doing-business-as names DataMEDS SI and Corexa Health SI and confirmed completion of its Dream Bowl token distribution.
The distribution was paid on September 9, 2026 to qualifying holders of record at the close of business on August 7, 2026. Entitlement is 50 tokens per common share, including shares issuable or deemed issuable from eligible securities. The tokens were listed on Biconomy in the third quarter of 2026. Receiving them requires a Datavault AI (DVLT) digital wallet and an Opt-In Agreement. The tokens are personal-use digital collectibles, confer no equity or monetary-payment rights, and may not have or maintain any value.
DataMeds AI (MEDS) reported that Corexa Pharmacy recorded preliminary, unaudited September 2026 revenue of more than $1 million. Revenue increased more than 66 percent from July 2026. Corexa Pharmacy is a division of wholly owned subsidiary Corexa Health, and its rebranding was completed in the first month of the third quarter.
The recently launched Health Lives Here mobile application offers Corexa Pharmacy as a fulfillment option for telehealth prescriptions. DataMeds AI has also closed the Helomics Corporation acquisition, which the company believes opens potential demand for oncology medications and nutritional support products. An upgrade of Corexa Pharmacy's physical location is underway to make it the flagship model for the Health Lives Here initiative with NFL Alumni Health.
DataMeds AI (MEDS) and Tollo Health launched the Health Lives Here app, initially focused on people using GLP-1 medications.
The app offers telehealth consultations, access to cash-pay branded GLP-1 medicines through DataMeds subsidiary Corexa Health’s pharmacy, Tollo Health nutrition products, wearable-data tracking and an AI health coach. NFL Alumni Health is helping market it. A national network is being established from Corexa’s 6,500+ independent-pharmacy network; Moose Pharmacy of Concord is the first participating store.
The companies intend to add patients with Long COVID in fourth-quarter 2026, followed by cancer patients. Direct-to-consumer lab tests are planned soon where permitted by law. DataMeds plans a digital-twin option—a virtual patient model—and a provider network for 2027.
DataMeds AI (MEDS) announced that interim Co-CEO Gerald Commissiong will present at the National Telehealth and Virtual Care Summit on September 28.
His “What Patients Really Want” session is scheduled for 9:15 a.m. PT in Las Vegas. He will discuss patient ownership of health data and the company’s Health Lives Here campaign and mobile healthcare application with NFL Alumni Health.
DataMEDS AI (MEDS) launched its new corporate website, www.DataMedsAI.com, following recent balance-sheet and business changes announced earlier in 2026.
The company previously acquired Helomics Corporation's AI Cancer Diagnostics Lab from Axe Compute and settled litigation related to the May 11, 2023 acquisition of Wellgistics, LLC. The settlement resulted in the extinguishment of approximately $19 million in liabilities and the retirement of 364,099 common shares. Interim Co-CEO Gerald E. Commissiong said the company is preparing to soft launch its Health Lives Here consumer application as part of a refreshed, AI‑centric marketing and branding strategy.